Edgen Stock·Oct 01 2025, 18:20戻る
戻る
Tempus AI Subsidiary, Ambry Genetics, Enhances Breast Cancer Risk Assessment Integration
Edgen Stock·Oct 01 2025, 18:20
[1] Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density[2] Ambry Genetics enhances breast cancer risk assessment tool with density data[3] Ambry Genetics announces improved EHR-integrated BC risk assessment solution - TipRanks